In our study of the FAERS, the risk signals were not found in anti‐CTLA4 agents, and only six cases of transplant rejection occurred in SOTRs treated with ipilimumab, which was the first ICI used for melanoma in 2011. Here, CTLA4 is linked to melanoma.